In recent multicenter clinical trials, CAR-T cells targeting the CD19 molecule have demonstrated high and durable response rates for patients with refractory or relapsed B-cell lymphoma (1, 2). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.